NewslettersHuman Immunology NewsDendritic Cell-Based In Situ Nanovaccine for Reprogramming Lipid Metabolism to Boost Tumor ImmunotherapyBy Noshin Noorjahan - December 8, 20230241Scientists engineered an in situ nanovaccine based on lipid metabolism-regulating and innate immune-stimulated nanoparticles.[ACS Nano]AbstractGraphical Abstract